...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy >Changes in Serum Asymmetric Dimethylarginine and Endothelial Markers Levels With Varying Periods of Hemodialysis
【24h】

Changes in Serum Asymmetric Dimethylarginine and Endothelial Markers Levels With Varying Periods of Hemodialysis

机译：血液透析期间不同，血清不对称二甲基精氨酸和内皮标记物水平的变化

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Asymmetric dimethylarginine (ADMA) as a uremia toxin is accumulated in end-stage renal disease (ESRD) patients. Elevated ADMA level has been shown to be predictive of cardiovascular diseases (CVDs) and all-cause mortality in ESRD. Therefore, we investigated the effect of prolonged hemodialysis (HD) treatment on the levels of serum ADMA, arginine, nitric oxide (NO), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1). Seventy-five patients (M/F=40/35) with chronic renal failure (CRF) and who were on HD were divided into five groups with differing treatment periods of HD; from 6 to 24 months to 97-120 months. Fifteen apparently healthy subjects acted as controls. The serum levels of ADMA, sICAM-1 and sVCAM-1 were increased in all patient groups compared to the control group. No significant difference was observed when the patient groups were compared in terms of HD treatment periods. Nitric oxide levels were lower in the three groups who were treated for periods of 49-72, 73-96, 97-120 months compared to the control group. The L-arginine to ADMA ratio was decreased in all patient groups compared to controls. Consequently, our investigations have shown that in HD continued for more than 4 years NO levels began to decrease significantly and the levels of serum ADMA, sICAM-1 and sVCAM-1 levels increased although this increase was not affected by the period in which hemodialysis treatment was applied.
机译：不对称的二甲基精氨酸（ADMA）作为尿毒症毒素在终末期肾脏疾病（ESRD）患者中积累。研究表明，升高的ADMA水平可预测心血管疾病（CVD）和ESRD的全因死亡率。因此，我们研究了延长血液透析（HD）处理对血清ADMA，精氨酸，一氧化氮（NO），可溶性细胞间粘附分子1（sICAM-1）和可溶性血管细胞粘附分子1（sVCAM- 1）。将75例慢性肾功能衰竭（CRF）并接受HD治疗的患者（M / F = 40/35）分为5组，分别接受不同的HD治疗时间。从6到24个月到97-120个月不等。十五名看似健康的受试者作为对照。与对照组相比，所有患者组的血清ADMA，sICAM-1和sVCAM-1均升高。当根据HD治疗时间比较患者组时，未观察到显着差异。与对照组相比，治疗49-72、73-96、97-120个月的三组中一氧化氮水平较低。与对照组相比，所有患者组的L-精氨酸与ADMA之比均降低。因此，我们的研究表明，在HD持续超过4年的时间里，NO水平开始显着降低，血清ADMA，sICAM-1和sVCAM-1水平升高，尽管这种升高不受血液透析治疗期间的影响已应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号